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Summary
The Centers for Disease Control and Prevention (CDC) continues to work closely with the World Health 
Organization (WHO) and other partners to better understand and manage the public health risks posed 
by Ebola Virus Disease (EVD). To date, no cases have been reported in the United States. The purpose 
o f this health update is 1) to provide updated guidance to healthcare providers and state and local health 
departments regarding who should be suspected o f having EVD, 2) to clarify which specimens should be 
obtained and how to submit for diagnostic testing, and 3) to provide hospital infection control guidelines.
U.S. hospitals can safely manage a patient with EVD by following recommended isolation and infection 
control procedures. Please disseminate this information to infectious disease specialists, intensive care 
physicians, primary care physicians, hospital epidemiologists, infection control professionals, and hospital 
administration, as well as to emergency departments and microbiology laboratories.
Background
CDC is working with the World Health Organization (WHO), the ministries of health of Guinea, Liberia, 
and Sierra Leone, and other international organizations in response to an outbreak of EVD in West Africa, 
which was first reported in late March 2014. As of July 27, 2014, according to WHO, a total of 1,323 
cases and 729 deaths (case fatality 55-60%) had been reported across the three affected countries. This 
is the largest outbreak of EVD ever documented and the first recorded in West Africa.
EVD is characterized by sudden onset of fever and malaise, accompanied by other nonspecific signs and 
symptoms, such as myalgia, headache, vomiting, and diarrhea. Patients with severe forms of the disease 
may develop hemorrhagic symptoms and multi-organ dysfunction, including hepatic damage, renal 
failure, and central nervous system involvement, leading to shock and death. The fatality rate can vary 
from 40-90%.
In outbreak settings, Ebola virus is typically first spread to humans after contact with infected wildlife and 
is then spread person-to-person through direct contact with bodily fluids such as, but not limited to, blood, 
urine, sweat, semen, and breast milk. The incubation period is usually 8 -10 days (ranges from 2-21 
days). Patients can transmit the virus while febrile and through later stages of disease, as well as 
postmortem, when persons touch the body during funeral preparations.
Patient Evaluation Recommendations to Healthcare Providers
Healthcare providers should be alert for and evaluate suspected patients for Ebola virus infection who 
have both consistent symptoms and risk factors as follows: 1) Clinical criteria, which includes fever of 
greater than 38.6 degrees Celsius or 101.5 degrees Fahrenheit, and additional symptoms such as severe 
headache, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage; AND 2) 
Epidemiologic risk factors within the past 3 weeks before the onset of symptoms, such as contact with 
blood or other body fluids of a patient known to have or suspected to have EVD; residence in— or travel 
to— an area where EVD transmission is active; or direct handling of bats, rodents, or primates from 
disease-endemic areas. Malaria diagnostics should also be a part of initial testing because it is a common 
cause of febrile illness in persons with a travel history to the affected countries.
CDC recommends testing for all persons with onset of fever within 21 days of having a high-risk 
exposure. A high-risk exposure includes any of the following:
• percutaneous or mucous membrane exposure or direct skin contact with body fluids of a person 
with a confirmed or suspected case of EVD without appropriate personal protective equipment 
(PPE),
• laboratory processing of body fluids of suspected or confirmed EVD cases without appropriate 
PPE or standard biosafety precautions, or
• participation in funeral rites or other direct exposure to human remains in the geographic area 
where the outbreak is occurring without appropriate PPE.
For persons with a high-risk exposure but without a fever, testing is recommended only if there are other 
compatible clinical symptoms present and blood work findings are abnormal (i.e., thrombocytopenia 
<150,000 cells/pL and/or elevated transaminases) or unknown.
Persons considered to have a low-risk exposure include persons who spent time in a healthcare facility 
where EVD patients are being treated (encompassing healthcare workers who used appropriate PPE, 
employees not involved in direct patient care, or other hospital patients who did not have EVD and their 
family caretakers), or household members of an EVD patient without high-risk exposures as defined 
above. Persons who had direct unprotected contact with bats or primates from EVD-affected countries 
would also be considered to have a low-risk exposure. Testing is recommended for persons with a low- 
risk exposure who develop fever with other symptoms and have unknown or abnormal blood work 
findings. Persons with a low-risk exposure and with fever and abnormal blood work findings in absence of 
other symptoms are also recommended for testing. Asymptomatic persons with high- or low-risk 
exposures should be monitored daily for fever and symptoms for 21 days from the last known exposure 
and evaluated medically at the first indication of illness.
Persons with no known exposures listed above but who have fever with other symptoms and abnormal 
bloodwork within 21 days of visiting EVD-affected countries should be considered for testing if no other 
diagnosis is found. Testing may be indicated in the same patients if fever is present with other symptoms 
and blood work is abnormal or unknown. Consultation with local and state health departments is 
recommended.
If testing is indicated, the local or state health department should be immediately notified. Healthcare 
providers should collect serum, plasma, or whole blood. A minimum sample volume of 4 mL should be 
shipped refrigerated or frozen on ice pack or dry ice (no glass tubes), in accordance with IATA guidelines 
as a Category B diagnostic specimen. Please refer to
http://www.cdc.gov/ncezid/dhcpp/vspb/specimens.html for detailed instructions and a link to the specimen 
submission form for CDC laboratory testing.
Recommended infection control measures
U.S. hospitals can safely manage a patient with EVD by following recommended isolation and infection 
control procedures, including standard, contact, and droplet precautions. Early recognition and 
identification of patients with potential EVD is critical. Any U.S. hospital with suspected patients should 
follow CDC’s Infection Prevention and Control Recommendations for Hospitalized Patients with Known or 
Suspected Ebola Hemorrhagic Fever in U.S. Hospitals (http://www.cdc.gov/vhf/ebola/hcp/infection- 
prevention-and-control-recommendations.html). These recommendations include the following:
• Patient placement: Patients should be placed in a single patient room (containing a private 
bathroom) with the door closed.
• Healthcare provider protection: Healthcare providers should wear: gloves, gown (fluid resistant 
or impermeable), shoe covers, eye protection (goggles or face shield), and a facemask.
Additional PPE might be required in certain situations (e.g., copious amounts of blood, other body
Testing of patients with suspected EVD should be guided by the risk level of exposure, as described
below:
fluids, vomit, or feces present in the environment), including but not limited to double gloving, 
disposable shoe covers, and leg coverings.
• Aerosol-generating procedures: Avoid aerosol-generating procedures. If performing these 
procedures, PPE should include respiratory protection (N95 filtering facepiece respirator or 
higher) and the procedure should be performed in an airborne isolation room.
• Environmental infection control: Diligent environmental cleaning and disinfection and safe 
handling of potentially contaminated materials is paramount, as blood, sweat, emesis, feces and 
other body secretions represent potentially infectious materials. Appropriate disinfectants for 
Ebola virus and other filoviruses include 10% sodium hypochlorite (bleach) solution, or hospital­
grade quaternary ammonium or phenolic products. Healthcare providers performing 
environmental cleaning and disinfection should wear recommended PPE (described above) and 
consider use of additional barriers (e.g., shoe and leg coverings) if needed. Face protection (face 
shield or facemask with goggles) should be worn when performing tasks such as liquid waste 
disposal that can generate splashes. Follow standard procedures, per hospital policy and 
manufacturers’ instructions, for cleaning and/or disinfection of environmental surfaces, 
equipment, textiles, laundry, food utensils and dishware.
Recommendations to Public Health Officials
If public health officials have a patient that is suspected of having EVD or has potentially been exposed 
and intends to travel, please contact CDC’s Emergency Operations Center 1 (770) 488-7100.
The Centers fo r  Disease Control and Prevention (CDC) protects people’s health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international
organizations.
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